Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Artesia, California 90701


The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This study will evaluate the safety and efficacy of two different doses of the Bimatoprost Ocular Insert, compared to an active control arm with timolol ophthalmic solution (0.5%).


Key Inclusion Criteria: - Written informed consent - At least 18 years of age - Diagnosis in both eyes of either primary open-angle glaucoma (POAG) or ocular hypertension - Best corrected-distance visual acuity score equivalent to 20/80 or better - Stable visual field - Central corneal thickness between 490 - 620 micrometers Inclusion Criteria at the Randomization Visit: - IOP for each eye is ≥ 23 mmHg at T=0hr, ≥ 20 mmHg at T=2hr and T=8hr. - Inter-eye IOP difference of ≤ 5.0 mmHg at T=0hr, T=2hr and T=8hr. - IOP for each eye is ≤ 30 mmHg at T=0hr, T=2hr and T=8hr. Key Exclusion Criteria: - Any known contraindication to prostaglandin analog (latanoprost, travoprost, bimatoprost, tafluprost) or timolol - A cardiac or pulmonary condition that in the opinion of the Investigator would contraindicate the use of beta-blocker drops - Cup-to-disc ratio of greater than 0.8 - Significant risk of angle closure due to pupil dilation, defined as a Shaffer classification of less than Grade 2 based on gonioscopy - Ocular, orbital, and/or eyelid surgery of any type within the past six (6) months from screening date - Laser surgery for glaucoma / ocular hypertension on one (1) or both eyes within the last six (6) months - Past history of any incisional surgery for glaucoma at any time - Past history of corneal refractive surgery - Corneal abnormalities that would interfere with accurate IOP readings with an applanation tonometer - Current participation in an investigational drug or device study or participation in such a study within 30 days of Screening - Inability to adequately evaluate the retina - Subjects who will require contact lens use during the study period. - Subjects who currently have punctal occlusion - Pregnant, lactating or of child-bearing potential and not using a medically acceptable form of birth control



Primary Contact:

Study Director
Gary A Walker, PhD
ForSight VISION 5

Backup Contact:


Location Contact:

Artesia, California 90701
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.